Walter Public Investments Inc. Has $6.25 Million Position in Cellebrite DI Ltd. $CLBT

Walter Public Investments Inc. lessened its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 11.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 453,532 shares of the company’s stock after selling 59,083 shares during the period. Walter Public Investments Inc. owned approximately 0.18% of Cellebrite DI worth $6,250,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its stake in Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after buying an additional 850 shares in the last quarter. Advisory Services Network LLC bought a new stake in shares of Cellebrite DI during the third quarter worth $40,000. CWM LLC increased its position in shares of Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after acquiring an additional 889 shares in the last quarter. First Horizon Corp raised its holdings in shares of Cellebrite DI by 421.8% during the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after acquiring an additional 2,337 shares during the period. Finally, Vestcor Inc bought a new stake in Cellebrite DI in the 3rd quarter valued at $70,000. 45.88% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the transaction, the executive directly owned 440,101 shares in the company, valued at $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 13,269 shares of company stock valued at $169,592 in the last ninety days. 5.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on CLBT shares. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Needham & Company LLC dropped their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. DA Davidson started coverage on Cellebrite DI in a report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Cellebrite DI presently has a consensus rating of “Moderate Buy” and an average target price of $21.40.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT opened at $15.65 on Friday. The company’s 50-day moving average price is $13.40 and its two-hundred day moving average price is $14.61. Cellebrite DI Ltd. has a one year low of $11.02 and a one year high of $19.98. The stock has a market capitalization of $3.90 billion, a PE ratio of 55.89, a price-to-earnings-growth ratio of 1.94 and a beta of 1.17.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.